225
Participants
Start Date
February 28, 2011
Primary Completion Date
November 30, 2012
Study Completion Date
October 31, 2014
etanercept
In Period 1, subjects will receive in a prefilled syringe with 1.0 ml (test article Etanercept (SC) once weekly . Additionally they will continue to take the background non steroidal anti inflammatory drug(NSAID) in the tolerated dose agreed upon by the attending Physician.
Background NSAID
Subject will continue to take a concomitant background non steroidal anti inflammatory drug(NSAID)as prescribed by their attending physician. The name and dose of this NSAID is the decision of the attending physician.
PLACEBO
In Period 1 will receive a prefilled syringe of Placebo for Etanercept Additionally they will continue to take the background non steroidal anti inflammatory drug(NSAID) in the tolerated dose agreed upon by the attending Physician.
Background NSAID
Subject will continue to take a concomitant background non steroidal anti inflammatory drug(NSAID)as prescribed by attending physician (dose drug selection as tolerated and agreed upon by the attending Physician).
Taipei Veterans General Hospital, Taipei
Chung-Ho Memorial Hospital, Kaohsiung Medical University, Kaohsiung City
Orszagos Reumatologiai es Fizioterapias Intezet/Klinikai Immunologiai es Reumatologiai Osztaly, Budapest
Budai Irgalmasrendi Korhaz, Budapest
Qualiclinic Egeszsegugyi Szolgaltato es Kutatasszervezo Kft., Budapest
Synexus Magyarorszag Egeszsegugyi Szolgaltato Kft., Budapest
Reuma Instituut, Hasselt
Kenezy Gyula Korhaz es Rendelointezet, Debrecen
Csolnoky Ferenc Korhaz, Veszprém
AZ Groeninge, Kortrijk
Universitair Ziekenhuis Gent, Ghent
Charite - Campus Benjamin Franklin, Medizinische Klinik I - Rheumatologie, Berlin
Hospital Reina Sofia, Córdoba
Mediscan Group, s.r.o., Praha 11 - Chodov
Complexo Hospitalario Universitario A Coruña, A Coruña
Schoen Klinik Hamburg-Eilbek, Abt. Rheumatologie und Klin. Immunologie, Hamburg
Fundacion Hospital Alcorcon, Alcorcón
CHU Lapeyronie, Immuno-Rhumatologie, Montpellier
CHU de Tours, Tours
MEDIGREIF Verwaltungs- und Betriebsgesellschaft Fachkrankenhaus Vogelsang-Gommern mbH, Vogelsang-Gommern
Chung Shan Medical University Hospital, Taichung
Hospital Virgen Macarena, Seville
Rheumazentrum Ruhrgebiet, Herne
Medical Plus s.r.o., Uherské Hradiště
Hôpital Cochin, Paris
Studienambulanz, Medizinische Klinik 3, Universitaetsklinikum Erlangen, Erlangen
Hopital de Bicetre, Le Kremlin-Bicêtre
Rheumatology Research Institute of Russian Academy of Medical Sciences, Moscow
Russian Cardiology Research-and-Production Complex, Moscow
Saint-Petersburg State Budgetary Healthcare Institution, Saint Petersburg
Limited Liability Company NMC Tomography, Saint Petersburg
Leningrad Regional Clinical Hospital, Saint Petersburg
Centro Medico Privado de Reumatologia, San Miguel de Tucumán
Consultorios Reumatológicos Pampa, Buenos Aires
Preventive Care Ltda., Chía
Ips Medicity S.A.S, Bucaramanga
Servimed Sas, Bucaramanga
Revmatologicky ustav, Prague
Meilahden kolmiosairaala, Helsinki
Kiljavan Lääketutkimus, Hyvinkää
Academic Medical Centre (AMC) / Division of Clinical Immunology and Rheumatology, Amsterdam
Leiden University Medical Center, Reumatologie, Leiden
Gachon University Gil Hospital, Incheon
Chonnam National University Hospital, Gwangju
Hanyang University Hospital, Seoul
Rhuematology Clinical Research Unit, Cambridge
Hampshire Hospitals NHS Foundation Trust, Basingstoke
Norfolk and Norwich University Hospital NHS Trust, Norwich
Russells Hall Hospital, Dudley
Whipps Cross University Hospital,, London
Lead Sponsor
Pfizer
INDUSTRY